Skip Navigation

Cardiovascular Research 2006 72(3):464-472; doi:10.1016/j.cardiores.2006.08.012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Anand-Srivastava, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Anand-Srivastava, M. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gq{alpha}/MAP kinase signaling pathways

Yuan Li, Shehla Hashim and Madhu B. Anand-Srivastava*

Department of Physiology, and Groupe de recherche sur le système nerveux autonome, (GRSNA) Faculty of Medicine, University of Montreal, Canada

* Corresponding author. Department of Physiology, Faculty of Medicine, University of Montreal, C. P. 6128, Succ. Centre-ville, Montreal, Quebec, Canada H3C 3J7. Tel.: +1 514 343 2091; fax: +1 514 343 2111. Email address: madhu.anand-srivastava{at}umontreal.ca

Objective: The present studies were undertaken to investigate if the activation of natriuretic peptide receptor-C (NPR-C) that has been shown to inhibit cell proliferation could also modulate the hypertrophic responses of vasoactive peptides in A10 vascular smooth muscle cells (VSMC).

Methods: For these studies A10 VSMC were incubated in the presence of angiotensin II (AngII), endothelin (ET-1) or arginine vasopressin (AVP) alone or in combination with C-ANP4–23 or NPR-C peptides for 24 h and were used for Western blotting and [3H]leucine incorporation. The different peptide fragments used were K461KYRITIERRNH472 (peptide-1) and H481RELREDSIRSH492 (peptide-3) with complete Gi activator sequences and R469RNHQEESNIGK480 (peptide-2) and I465TIERRNH472 (peptideY) with partial Gi activator sequences. The other peptide used had no structural specificity, (Q473EESNIGK480; peptide X) or was the scrambled peptide control for peptide-1 (ITIYKKRRNHRE; peptide Z).

Results: AngII, ET-1 and AVP significantly stimulated protein synthesis in these cells as determined by 3H-leucine incorporation, which was inhibited by peptides 1, 2 and 3 and not by peptides X, Y or Z in a concentration-dependent manner with an apparent Ki between 1–10 nM. In addition, C-ANP4–23 also inhibited protein synthesis stimulated by AngII, ET-1 and AVP; whereas basal protein synthesis in these cells was not inhibited by C-ANP4–23 or by the peptide fragments. Furthermore, AngII-, AVP- and ET-1-induced stimulation of protein synthesis was inhibited by PD98059 (MEK inhibitor) and wortmannin (P13K inhibitor) and this inhibition was potentiated by peptide-1. In addition, peptide-1 was also able to inhibit vasoactive peptide-induced phosphorylation of ERK1/2 and AKT and enhanced the expression of Gq{alpha} protein in these cells.

Conclusions: These data suggest that C-ANP4–23 and small peptide fragments containing 12 amino acids from different regions of cytoplasmic domain of NPR-C could modulate vasoactive peptide-stimulated protein synthesis through Gq{alpha}/MAP kinase/P13K and AKT pathways.

KEYWORDS NPR-C; Peptide-1; Vasoactive peptides; Protein synthesis; ERK1/2; Gq{alpha}; VSMC

Abbreviations: C-ANP4–23, [des(Glu18, Ser19, Glu20, Leu21, Gly22)ANP4–23-NH2] • AngII, angiotensin II • AVP, arginine vasopressin • ET-1, endothelin • MAPK, mitogen-activated protein kinase • PI3K, phosphatidylinositol 3-kinase • AKT, protein kinase B • VSMC, vascular smooth muscle cells


* This study was supported by a grant from the Canadian Institutes of Health Research (MOP 13661).

Time for primary review 22 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Physiol.Home page
R. A. Rose and W. R. Giles
Natriuretic peptide C receptor signalling in the heart and vasculature
J. Physiol., January 15, 2008; 586(2): 353 - 366.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.